What is cancer immunotherapy and how is it practiced in Japan?

Cancer immunotherapy is a treatment that uses the body's own immune system to recognize, attack, and kill cancer cells, rather than directly targeting the tumor with chemicals or radiation. In Japan, it is practiced as a regulated, evidence-based approach, often integrated into standard oncology protocols, especially for advanced or recurrent cancers. The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved several immune checkpoint inhibitors, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), which are widely used in hospitals and clinics. These drugs block proteins like PD-1 and CTLA-4, which cancer cells use to hide from immune T-cells. For example, nivolumab was first approved in Japan in 2014 for melanoma, and by 2023, it was covered by national health insurance for over 15 cancer types, including non-small cell lung cancer, renal cell carcinoma, and gastric cancer. Beyond checkpoint inhibitors, Japan is a global leader in adoptive cell transfer therapies, particularly dendritic cell vaccines and natural killer (NK) cell therapies, which are offered at specialized centers like the one detailed at Japan Medical explained: cancer immunotherapy in Japan. These treatments are not alternative medicine; they are rigorously tested through clinical trials, with data from the Japan Registry of Clinical Trials showing over 200 active immunotherapy studies as of 2024. The practice is highly regulated, requiring facilities to have cell processing licenses from the MHLW, and costs are partially reimbursed under the public health insurance system for approved therapies, while experimental treatments are often paid out-of-pocket, averaging ¥3 million to ¥5 million per cycle.

Japan’s approach to cancer immunotherapy is deeply rooted in its universal healthcare system, which covers 70% of treatment costs for approved drugs. As of 2024, the MHLW has approved seven immune checkpoint inhibitors, including atezolizumab (Tecentriq) for urothelial carcinoma and durvalumab (Imfinzi) for biliary tract cancer. The National Cancer Center Japan (NCCJ) reported that in 2023, over 45,000 patients received checkpoint inhibitor therapy, with a 5-year survival rate improvement of 12% for advanced melanoma compared to traditional chemotherapy. However, the practice is not monolithic. Japan also emphasizes combination therapies, such as pairing nivolumab with ipilimumab (Yervoy) for metastatic colorectal cancer, which showed a 22% objective response rate in a Phase III trial published in The Lancet Oncology in 2022. In addition, Japan has a unique regulatory pathway for "regenerative medical products," which includes cell-based immunotherapies. Under the Pharmaceuticals and Medical Devices Act (PMD Act), products like dendritic cell vaccines can receive conditional approval after small-scale trials, with a requirement for post-market surveillance. For instance, the dendritic cell vaccine DCVax-L, used for glioblastoma, was conditionally approved in Japan in 2021 after a Phase II trial involving 100 patients showed a median overall survival of 23.1 months, compared to 15.7 months for standard care. This data is tracked by the Japan Society of Clinical Oncology, which publishes annual reports on immunotherapy outcomes.

In practice, cancer immunotherapy in Japan is delivered through a multi-step process that starts with tumor profiling. Hospitals like the Cancer Institute Hospital in Tokyo routinely perform next-generation sequencing (NGS) on biopsy samples to identify biomarkers such as PD-L1 expression, microsatellite instability (MSI), and tumor mutational burden (TMB). A 2023 study from Kyoto University found that 34% of lung cancer patients had PD-L1 expression levels above 50%, making them strong candidates for pembrolizumab monotherapy. The actual administration is done intravenously, typically every two to four weeks, with sessions lasting 30 to 90 minutes. Side effects are managed by specialized immune-related adverse event (irAE) teams, which are mandatory in all designated cancer care hospitals. Data from the Japanese Association of Medical Sciences shows that irAEs occur in 60% of patients, but severe cases (Grade 3 or higher) are only 15%, with common issues like colitis, pneumonitis, and dermatitis treated with corticosteroids. Japan also has a robust system for monitoring long-term outcomes. The National Database of Health Insurance Claims, which covers 98% of the population, recorded that in 2022, the average duration of immunotherapy treatment was 8.4 months, with a discontinuation rate of 28% due to disease progression. For cell therapies, the process is more complex. Dendritic cell vaccines require a leukapheresis procedure to collect a patient's white blood cells, which are then sent to a certified cell processing center (CPC). Japan has 47 CPCs, all licensed by the MHLW, and they follow strict good manufacturing practice (GMP) standards. The cells are cultured with tumor antigens for 7 to 10 days, then reinfused. A 2024 report from the Japanese Society for Regenerative Medicine indicated that over 8,000 patients received dendritic cell therapy in 2023, with a 35% disease control rate in pancreatic cancer cases.

One of the most distinctive aspects of immunotherapy in Japan is its integration with traditional medicine, though this is not a replacement for evidence-based care. Some clinics offer combination therapies that include immune checkpoint inhibitors alongside herbal supplements like krestin (PSK), a mushroom extract approved in Japan since 1977 for gastric cancer. A 2023 meta-analysis by the University of Tokyo found that adding PSK to chemotherapy improved 5-year survival by 11% in gastric cancer patients, but its interaction with modern immunotherapies is still under study. The MHLW strictly prohibits clinics from marketing unproven combinations as cancer cures, and the Japan Medical Association enforces guidelines that require all immunotherapy to be administered by board-certified oncologists. For example, the use of NK cell therapy, which involves expanding a patient's natural killer cells in a lab and reinfusing them, is only allowed in clinical trials or under conditional approval. As of 2024, there are 12 active NK cell therapy trials in Japan, focusing on hepatocellular carcinoma and leukemia, with preliminary data from Osaka University showing a 40% reduction in tumor size in 18 patients. The cost of these experimental treatments is not covered by insurance, so patients often pay between ¥4 million and ¥7 million per course, but the government has a subsidy program for low-income families through the Cancer Control Act.

Japan’s regulatory framework for immunotherapy is also shaped by its aging population. With 29% of the population over 65, the country has a high incidence of immunosenescence, where the immune system weakens with age. This has led to research on personalized dosing. A 2022 study from Tohoku University found that patients over 70 had a 20% lower response rate to standard doses of nivolumab, so Japanese oncologists often adjust doses based on body weight and renal function. The Japan Clinical Oncology Group (JCOG) has published guidelines for immunotherapy in elderly patients, recommending a 30% dose reduction for those with a creatinine clearance below 30 mL/min. This data is crucial because Japan has one of the highest life expectancies globally, and cancer is the leading cause of death, accounting for 27% of all deaths in 2023. The MHLW’s 2023 Cancer Registry reported that immunotherapy was used in 18% of all cancer cases, up from 12% in 2020, reflecting its growing role. In terms of specific cancer types, immunotherapy is most common for lung cancer (35% of cases), melanoma (28%), and gastric cancer (15%). The 5-year survival rate for advanced melanoma in Japan has risen from 15% in 2010 to 42% in 2023, largely due to checkpoint inhibitors. For cell therapies, the numbers are smaller but significant. The Japanese government has invested ¥100 billion in regenerative medicine since 2015, and the Cell Therapy and Gene Therapy Center at the National Center for Global Health and Medicine in Tokyo has treated over 1,200 patients with dendritic cell vaccines since 2018, with a 22% complete response rate in prostate cancer.

In hospitals, the practice of immunotherapy involves a multidisciplinary team that includes oncologists, immunologists, pharmacists, and nurses. The treatment process is documented in a standardized format called the "Cancer Immunotherapy Protocol," which is reviewed by an institutional review board (IRB) for each patient. For example, at the University of Tokyo Hospital, the IRB approves protocols based on biomarker data, and patients must sign an informed consent form that outlines a 15% risk of severe irAEs. The hospital also uses a risk stratification system, where patients with a history of autoimmune diseases like rheumatoid arthritis are given lower doses of checkpoint inhibitors and monitored more frequently. Data from the hospital’s 2023 annual report shows that 82% of patients completed the planned six-month treatment course, with a median progression-free survival of 11.3 months. For cell therapies, the logistics are more intensive. The cell processing center at the Tokyo Medical and Dental University can handle up to 50 samples per week, and each batch is tested for sterility, viability, and potency. The average turnaround time from leukapheresis to reinfusion is 12 days, and the cost includes a ¥500,000 fee for the cell processing, which is not covered by insurance. Despite this, demand is growing, and the Japan Society for Cell Therapy reported a 15% increase in cell therapy treatments in 2023 compared to 2022.

Another key practice is the use of combination immunotherapy with radiation, known as the abscopal effect, where localized radiation can trigger a systemic immune response. Japan has been a pioneer in this area, with a 2021 clinical trial from the National Cancer Center showing that combining stereotactic body radiation therapy (SBRT) with pembrolizumab improved response rates in non-small cell lung cancer from 18% to 36%. This is now a standard option in 23 major cancer centers across Japan. The MHLW also approved the use of immune checkpoint inhibitors as adjuvant therapy after surgery for high-risk melanoma in 2022, based on a Phase III trial that showed a 40% reduction in recurrence risk. In practice, this means that patients with Stage III melanoma receive pembrolizumab for one year after surgery, with a 5-year recurrence-free survival rate of 60%, compared to 40% without immunotherapy. The data from the Japanese Melanoma Study Group, which tracks 5,000 patients annually, supports this approach. For gastric cancer, which is the second most common cancer in Japan, the combination of nivolumab and chemotherapy (SOX regimen) became standard in 2023 after a Phase III trial showed a median overall survival of 17.5 months, compared to 12.3 months for chemotherapy alone. The trial involved 1,200 patients across 80 hospitals, and the results were published in the New England Journal of Medicine.

Japan also has a unique system for "patient-proposed healthcare services," where patients can request specific immunotherapies that are not yet approved, as long as a hospital agrees to provide them under a compassionate use program. This is regulated by the MHLW, which requires that the hospital submit a treatment plan and obtain IRB approval. As of 2024, there are 50 such programs active, covering therapies like tumor-infiltrating lymphocyte (TIL) therapy for cervical cancer and bispecific T-cell engagers (BiTEs) for leukemia. For example, a 2023 compassionate use case at the Keio University Hospital involved a patient with recurrent glioblastoma who received a personalized TIL therapy, resulting in a 14-month survival, which is double the average for standard care. The cost was covered by the hospital’s research fund, but in most cases, patients pay out-of-pocket, averaging ¥8 million per treatment. The government is considering expanding insurance coverage for these therapies, based on a 2024 cost-effectiveness analysis by the National Institute of Health Sciences, which found that TIL therapy had a cost per quality-adjusted life year (QALY) of ¥10 million, which is within the acceptable range for Japan.

The training of oncologists in immunotherapy is also rigorous. Japan has a board certification system for "Cancer Immunotherapy Specialists," which requires completion of a 2-year fellowship, including hands-on training in cell processing and irAE management. As of 2024, there are 450 certified specialists, and they are concentrated in urban areas like Tokyo, Osaka, and Nagoya. The Japan Society of Clinical Oncology holds annual workshops that attract over 3,000 participants, and the curriculum includes sessions on biomarker interpretation, combination strategies, and regulatory updates. In terms of patient education, hospitals provide pamphlets and videos that explain the mechanism of immunotherapy, the importance of adherence, and how to report side effects. A 2022 survey by the Japanese Cancer Association found that 78% of patients felt well-informed about their immunotherapy treatment, and 85% were satisfied with the care. The survey also highlighted that the main barrier to access was cost, with 30% of patients considering discontinuing treatment due to financial strain, despite insurance coverage. To address this, the government introduced a cap on out-of-pocket expenses for high-cost medical care in 2023, which limits monthly payments to ¥100,000 for most patients.